id:"swepub:oai:lup.lub.lu.se:25a4a995-8317-400e-b971-633f0b26302c"
Search: id:"swepub:oai:lup.lub.lu.se:25a4a995-8317-400e-b971-633f0b26302c" > Regional variation ...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Kinhult, SaraLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital (author)
Regional variation i användningen av TTF vid glioblastombehandling
- Article/chapterSwedish2023
Publisher, publication year, extent ...
- 2023
Numbers
- LIBRIS-ID:oai:lup.lub.lu.se:25a4a995-8317-400e-b971-633f0b26302c
- https://lup.lub.lu.se/record/25a4a995-8317-400e-b971-633f0b26302cURI
Supplementary language notes
- Language:Swedish
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Varying forms of title
- Regional variation in usage of TTF (Optune)
Notes
- The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide. Based on a randomised trial, showing five months increased survival, TTF has been introduced in the management of patients with good performance status. Data from the Swedish national quality registry for CNS tumours have been analysed for TTF usage. The results demonstrate that 65 percent of the patients accepted treatment with TTF. More than half of the treated patients interrupted treatment due to low compliance or their own wish. Median treatment time was 164 days, with a range from 0 to 774 days. There was a large variation between different regions in how many patients were offered TTF treatment. A non-significant trend to better survival was seen for the group of TTF-treated patients compared to individually matched controls. In summary, TTF is a new treatment for glioblastoma, with potential to prolong survival also in real world patients. Today, the treatment is not offered equally to all patients, despite national guidelines.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Tavelin, BjörnUmeå University (author)
- Löfgren, David (author)
- Rosenlund, LenaUniversity of Gothenburg (author)
- Sandström, MariaNorrland University Hospital (author)
- Strandeus, Michael (author)
- Henriksson, RogerNorrland University Hospital (author)
- TumörmikromiljöSektion I (creator_code:org_t)
Related titles
- In:Lakartidningen1200023-7205
Internet link
Find in a library
- Lakartidningen (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Kinhult, Sara
- Tavelin, Björn
- Löfgren, David
- Rosenlund, Lena
- Sandström, Maria
- Strandeus, Micha ...
- show more...
- Henriksson, Roge ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Lakartidningen
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
